BridgeBio Pharma, Inc. terminated Equity Distribution Agreement, dated May 4, 2023 with Goldman Sachs & Co. LLC and Leerink Partners LLC (formerly known as SVB Securities LLC) (effective 2026-05-07).
“On May 7, 2026, in connection with entering into the Agreement, the Company agreed with Goldman Sachs and Leerink Partners (formerly known as SVB Securities LLC), to terminate that certain Equity Distribution Agreement, dated May 4, 2023, by and among the Company, Goldman Sachs and Leerink Partners, effective as of May 7, 2026.”
Material Agreements
BridgeBio Pharma, Inc. entered into Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC valued at $500,000,000 (effective 2026-05-07).
“On May 7, 2026, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Goldman Sachs & Co. LLC (“Goldman Sachs”) and Leerink Partners LLC (“Leerink Partners”, and together with Goldman Sachs, the “Sales Agents”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at its sole discretion and pursuant to a prospectus supplement, shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $500,000,000 (the “Placement Shares”), through the Sales Agents.”
Earnings Releases
BridgeBio Pharma, Inc. reported the first quarter ended March 31, 2026 results: revenue $194.5 million.
“except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates - $194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued”
Debt Financings
BridgeBio Pharma, Inc. incurred convertible notes of $632.5 million aggregate principal amount with qualified institutional buyers at 0.75% per year maturing February 1, 2033.
“BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026”
Material Agreements
BridgeBio Pharma, Inc. entered into 0.75% Convertible Senior Notes due 2033 Indenture with U.S. Bank Trust Company, National Association valued at $632,500,000 aggregate principal amount (effective 2026-01-21).
“On January 21, 2026, BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026 (the “Indenture”), between BridgeBio and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers (the “Note Offering”) pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).”
Governance Changes
BridgeBio Pharma, Inc.: Amendment to Certificate of Incorporation to include an officer exculpation provision limiting liability of certain officers as permitted by Delaware law (effective 2025-06-23).
“an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time (the “Certificate of Incorporation”) to limit the liability of certain officers of the Company as permitted under current Delaware law (the “Officer Exculpation Amendment”).”
Brian C. Stephenson departed as Chief Financial Officer at BridgeBio Pharma, Inc..
“The employment of Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc. (the “Company”), ended on March 17, 2025 (the “Effective Date”).”
Neil Kumar changed role as President at BridgeBio Pharma, Inc..
“Neil Kumar, Ph.D. stepped down as President”
Thomas Trimarchi was appointed as President and Chief Operating Officer at BridgeBio Pharma, Inc..
“Thomas Trimarchi was appointed as the Company’s President and Chief Operating Officer”
Earnings Releases
BridgeBio Pharma, Inc. reported financial results for first quarter ended March 31, 2024.
“BridgeBio Pharma, Inc. reported recent business updates and its financial results for the first quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.